V
Vernal Biosciences
Manufacturer of high purity mRNA for research and clinical use
About Vernal Biosciences
Vernal Biosciences is a Contract Development and Manufacturing Organization (CDMO) specializing in the production of high-quality mRNA (messenger RNA) for use in advanced therapeutics. The company's primary market is the biotech and pharmaceutical industry, specifically organizations that require mRNA for research and development (R&D) and clinical trials.
Read full description
Vernal Biosciences operates on a transactional business model, providing on-demand, high-purity mRNA and LNP-mRNA (Lipid Nanoparticle mRNA) supplies and services. This model allows clients to avoid the cost and risk of building their own teams and facilities for mRNA production. Instead, they can focus on other high-value operations such as drug discovery, clinical development, and marketing.
The company's platform and analytical methods aim to eliminate the guesswork and lengthy development cycles often associated with manufacturing processes in the advanced therapeutics field. Vernal Biosciences ensures consistent quality across all scales of mRNA and LNP-mRNA production, providing a de-risked, advanced staging ground for research and clinical supply.
In addition to mRNA production, Vernal Biosciences also offers associated services such as process development and quality control methods. The company's quality-by-design driven platform technologies cover the entire value chain of mRNA medicines, accommodating all mRNA needs.
In summary, Vernal Biosciences is a key player in the mRNA production sector, providing high-quality mRNA and associated services to biotech and pharmaceutical companies.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Colchester, United States
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 60.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Vaccines, Genetics and genomics, Biotech and Pharma, mRNA Medicines, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jun 2023 | $20M | $105M | Vermont Center for Emerging Technologies · Ampersand Capital Partners · Dynamk Capital · Charles River Laboratories International | ↗ |
| EARLY VC✓Equity / VC | Jun 2022 | $21M | $84M | Alloy Therapeutics · Dynamk Capital · Charles River Laboratories International · ATUM | ↗ |
Growth signals
Latest recorded traffic for Vernal Biosciences is 2.1K monthly website visits, down 12.5% over the last three months. Vernal Biosciences's team declined 58.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Vermont Center for Emerging Technologies
Alloy Therapeutics
Series A4 investors entered at this stage
Dynamk Capital
Ampersand Capital Partners
Charles River Laboratories International
ATUM
Other known investors1 additional known investor
VCET Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vernal Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vernal Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.